Hepatitis C virus carriers with persistently normal aminotransferase levels: Healthy people or true patients?

Digestive and Liver Disease

Volumn 32, Issue 7, 2000, Pages 634-643

  Puoti, C ^a   Castellacci, R ^a   Montagnese, F ^a  

^a NONE   (Italy)

Author keywords

Aminotransferase; HCV; Histology; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; POPULATION RESEARCH; SCREENING TEST; SEROPREVALENCE; TREATMENT INDICATION; VIRUS CARRIER; VIRUS DETECTION;

EID: 0033659668     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1590-8658(00)80850-6     Document Type: Article

References (77)

1. Asymptomatic infection with hepatitis C virus
2. Follow up of blood donors positive for anti bodies to hepatitis C virus
3. Therapy of chronic viral hepatitis: A critical view
4. Clinical, histological and virological features of hepatitis C virus carriers with persistently normal aminotransferase levels
5. Liver histology in anti-HCV positive subjects with normal ALT levels
6. Phylogenetic analysis of hepatitis C isolates: Correlation to viremia, liver function tests, and histology
7. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
8. HCV viraemia and liver injury in symptom-free blood donors
9. Liver histology in hepatitis C infection: A comparison between patients with persistently normal or abnormal transaminases
10. Does the healthy hepatitis C virus carrier state really exist? An analysis using Polymerase Chain Reaction
11. Hepatitis C-related chronic liver disease among asymptomatic blood donors in the North West of England
12. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features
13. Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects
14. Assessment of liver function in patients with hepatitis C and normal transaminase levels
15. Therapy of hepatitis C: Patients with normal aminotransferase levels
16. Diagnosis of hepatitis C
17. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection
18. Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection
19. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus
20. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test
21. Treatment in patients with normal ALT levels
22. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
23. Prevalence of anti-HCV antibodies among patients hospitalized in a Medical Unit
24. Prevalence of chronic liver disease in the general population of Northern Italy: The Dyonisos Study
25. High prevalence of hepatitis C virus infection in a small central Italian town: Lack of evidence of parenteral exposure
26. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based-survey in Southern Italy
27. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values
28. A retrospective study of hepatitis C virus carriers in a local endemic town in Japan
29. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection
30. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities
31. Normal aminotranferase concentrations in patients with antibodies to hepatitis C virus
32. Long-term observation of HCV-positive patients with normal ALT values: Persistence of a clinically healthy state
33. Risk of ALT increase among asymptomatic HCV RNA carriers. A 30-month follow-up
34. Natural history of hepatitis C virus carriers with persistently normal transaminase levels
35. Circulating HCV-RNA, HCV genotypes, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study
36. High prevalence of antibodies to hepatitis C virus among family members of patients with anti-HCV-positive chronic liver disease
37. Do symptomless HCV carriers spread infection to their relatives?
38. Persistent hepatitis C viraemia without liver disease
39. Management of the asymptomatic HCV carriers with normal ALT
40. Natural history of chronic hepatitis C
41. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
42. Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis?
43. Alanine aminotransferase measurements and histological disease in hepatitis C
44. Detection of plus and minus HCV-RNA in normal liver of anti-HCV positive patients
45. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study
46. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels
47. Phylogenetic analysis of hepatitis C isolates: Correlation to viremia, liver function tests, and histology
48. Apoptosis and hepatobiliary disease
49. The role of apoptosis in patients with chronic HCV and persistently normal ALT levels
50. Lack of association between type of hepatitis C virus, serum load and severity of liver disease
51. Intrahepatic HCV RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C
52. Hepatitis C virus type 1b (II) infection in France and Italy
53. Genotypic analysis of hepatitis C virus in American patients
54. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels
55. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease
56. Levels of hepatitis C virus in blood donors infected with different viral genotypes
57. Hepatitis C viral quasi species and liver damage in patients with chronic hepatitis C virus infection
58. Genotype, serum level of hepatitis C virus RNA and liver histology as predictor of response to interferon-α2a therapy in Japanese patients with chronic hepatitis C
59. Effect of genotypes on the quantitation of hepatitis C virus (HCV) RNA in clinical samples using the Amplicor HCV monitor assay and the Quantiplex HCV RNA 2.0 assay (bDNA)
60. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infection
61. Humoral response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
62. Dynamics of hypervariable region 1 in hepatitis C virus infection and correlation with clinical and virological features of liver disease
63. Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels
64. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels
65. Histological grading and staging of chronic hepatitis
66. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States
67. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: The role of interferon alfa2b therapy
68. The role of liver biopsy in hepatitis C
69. Interferon for hepatitis C
70. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity
71. Poor efficacy of alpha interferon treatment in patients affected by chronic hepatitis C with normal or near normal ALT levels
72. Interferon alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment
73. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis
74. Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels
75. Interferon-alpha 2b therapy in low-activity hepatitis C: A pilot study